tbuckley/cabot-search huggingface dataset:
Combined treatment with high-dose methotrexate and whole brain radiation improves survival in primary central nervous system lymphoma (PCNSL)
Authors: M. A. Abdelsalam, G. Hussainy, S. Akhtar, I. Maghfoor, A. Elweshi, Y. Khafaga, H. Alhuseini, M. Rahal, M. Alshabana
Journal: Journal of Clinical Oncology (2007)

18520 Background: Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor, cranial irradiation alone rarely result in long term disease control or prolonged survival. We analyzed our data for the impact of adding high dose methotrexate (HDMTX) prior to whole brain irradiation (WBI). Methods: All patients with PCNSL diagnosed and managed during 1991–2004 were identified from Oncology Data Unit. Patient’s characteristics, prognostic factors, details of treatment and outcome were reviewed. Sixty-two patients were identified, 10 were excluded (4 had WBI &lt; 40 Gy and 6 had no treatment). Radiation alone was considered curative with a dose ≥ 40 Gy. Combined modality therapy included 3–4 cycles of HDMTX (3gm/m2) followed by WBI Results: 52 patients were analyzed for outcome. 36 had WBI, dose ≥40 Gy, 16 received 3–4 cycle of HDMTX followed by WBI (chemo-radiotherapy (CRT)). Median age was 48.2 years; 42 years in CRT group, 51 years in WBI. Patients characteristics were comparable between two groups except for higher multifocal tumor in CRT group (92% vs. x22%, p=0.029). Median follow is 12.83±6.4 months. Results are shown in Table . HR for event is 0.64 (95% CI was 0.52–0.98) and for death 0.58 (95% CI was 0.48–0.92), both in favor of CRT. Univariate regression analysis using one-way analyses of variance (ANOVA) and multivariate Cox regression analysis for prognostic factors including age (&lt; 60 vs. ≥60), ECOG PS (0–2 vs. 3–4), extent of surgery (biopsy vs. debulking), solitary vs mutifocal tumor and dose of radiation therapy (&lt; 50Gy vs. ≥50Gy) failed to identify any prognostic factor. Conclusions: This retrospective comparison supports other phase II trials results that high dose methotrexate followed by WBI in PCNSL improves outcome. [Table: see text] No significant financial relationships to disclose.
Abstract 1195: Oct-1 as a potential biomarker for oxaliplatin-based therapy in non-small cell lung cancer
Authors: Orli Kadoch, Tong Li, Liang You, Sook-Wah Yee, Kathleen Giacomini, David M. Jablons, Zhidong Xu
Journal: Cancer Research (2010)

Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death in the developed world. Platinum-based chemotherapy, including agents such as cisplatin and carboplatin, represents the standard therapeutic regimen in both adjuvant and metastatic settings. However, these treatments are often associated with profound dose-limiting toxicities in some patients. It is therefore important to develop a rational basis for individualized treatment of NSCLC. Recently, oxaliplatin, a third generation anti-neoplastic platinum-based agent has been explored as a component of therapy for NSCLC. Tumor-specificity and anti-tumor efficacy of oxaliplatin were correlated with active drug influx and OCT-1 expression in colon cancer, but expression of OCT-1 has not been evaluated in NSCLC until now. In this study, we hypothesize that OCT-1 is a major determinant of response to oxaliplatin in lung cancer expressing high levels of the gene and could serve as a predictive biomarker for oxilaplatin-based therapy. We investigated the expression of OCT-1 in lung adenocarcinoma and squamous cell carcinoma specimens using immunohistochemistry (IHC)-based methods. IHC staining was performed on 172 paired specimens on tissue microarrays (TMA) developed in our Thoracic Oncology Program. An anti-human OCT-1 monoclonal antibody and biotinylated anti-rabbit secondary antibody were used for hybridization. The IHC slides were then developed using ABC-DAB procedures and images were acquired using the Aperio ScanScope CS and XT digital slide acquisition systems. We observed 65 of 91 (71%) adenocarcinomas and 41 of 71 (57%) squamous cell carcinomas to be positive for OCT-1 expression. We identified low levels or absence of OCT-1 expression in the majority of paired normal lung specimens (74%). The OCT-1 levels were significantly higher in both adenocarcinomas and squamous cell carcinomas than in matched normal lung (p&amp;lt;0.001). In addition, the percentage of specimens expressing OCT-1 was significantly higher in adenocarcinomas than in squamous cell carcinomas (p&amp;gt;0.05), suggesting more potential efficacy of oxilaplatin in patients with adenocarcinomas. In conclusion, OCT-1 was more abundantly expressed in both lung adenocarcinomas and squamous cell carcinomas than in matched normal specimens. The expression status of OCT-1 could serve as a novel predictive biomarker for the selection of patients with NSCLC for oxaliplatin-based chemotherapy. (Supported by NIH grant CA 093708-01A3 and TRDRP grant 17FT-0126) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1195.
INFLUENCE OF SURROUNDING RIM MORPHOLOGY ON PROCEDURE SUCCESS RATE OF TRANSCATHETER ATRIAL SEPTAL DEFECT CLOSURE
Authors: Teiji Akagi, Yasufumi Kijima, Yoichi Takaya, Koji Nakagawa, Hiroki Oe, Shunji Sano, Hiroshi Ito
Journal: Journal of the American College of Cardiology (2015)
THE ASSOCIATION BETWEEN ANKLE BRACHIAL INDEX AND 10 YEARS CARDIOVASCULAR EVENTS IN HEMODIALYSIS PATIENTS: FROM IMPACT-ABI REGISTRY
Authors: Tomoaki Mochidome, Kunihiko Shimizu, Wataru Shoin, Mikiko Harada, Yasushi Ueki, Koji Yoshie, Masatoshi Minamisawa, Yasutaka Oguchi, Naoto Hashizume, Hitoshi Nishimura, Naoyuki Abe, Takashi Miura, Soichiro Ebisawa, Takahiro Takeuchi, Hirohiko Motoki, Ayako Okada, Yuji Shiba, Atsushi Izawa, Jun Koyama, Uichi Ikeda
Journal: Journal of the American College of Cardiology (2016)
Cardiac Output and Other Hemodynamic Variables during External Cardiac Massage in Man
Authors: L. R. M. Del Guercio, Rama P. Coomaraswamy, David State
Journal: New England Journal of Medicine (1963)

SUCCESSFUL closed-chest cardiac resuscitation in man has been well documented,1 , 2 but little is known of the physiologic effects of this technic. The question arises how much blood flow can actually be produced by compression of the human heart between the sternum and vertebral column. Systemic arterial pressures have been recorded during performance of this method of resuscitation in man,3 4 5 6 but fluid shock waves are not a direct indication of flow. As Weiser and his group7 pointed out, "high systolic pressures may be due in part to catheter fling and in part to direct transmission of pressures applied to the closed . . .
P1080 TREATMENT CESSATION IS SAFE AND EFFECTIVE AFTER PROLONGED SUPPRESSION WITH NUCLEOSIDES/NUCLEOTIDES IN HBV E-ANTIGEN NEGATIVE, NON-CIRRHOTIC PATIENTS
Authors: V. Patwardhan, N. Sengupta, A. Bonder, D. Lau, N. Afdhal
Journal: Journal of Hepatology (2014)
Endoscopic Ultrasound (EUS)-guided Fine Needle Biopsy (FNB) in the histological evaluation of patients with chronic pancreatitis
Authors: J Iglesias-Garcia, J Lariño-Noia, I Abdulkader, J Forteza, JE Dominguez-Muñoz
Journal: Endoscopy (2006)

Background: Histological diagnosis of chronic pancreatitis has been classically limited to the study of surgical specimens. Since pancreatic biopsies are rarely done in the context of chronic pancreatitis, histological characteristics at different stages of the disease are unknown. Aim: To evaluate the histological characteristics of chronic pancreatitis in samples obtained by pancreatic EUS-FNB, and the relationship with EUS findings. Methods: Fourteen consecutive patients (14 male, mean age 66 years, range 17–81 years) with known chronic pancreatitis, who underwent EUS-FNB for the study of pancreatic masses were included. EUS-FNB was performed under conscious sedation with a 22G needle guided by the lineal scanning Pentax FG-38UX echoendoscope. EUS criteria for the diagnosis of chronic pancreatitis were evaluated: parenchymal criteria included hyperechoic foci, hyperechoic strands, lobularity, cysts and calcifications; and ductal criteria included dilation, duct irregularity, hyperechoic duct margins, visible side-branches and intraductal calcifications. Following histological features were evaluated: presence of acini, ductal epithelium, fibrotic tissue (collagen) and inflammatory infiltration. Results: Adequate tissue sample for histological evaluation was obtained in all cases. Infiltration by inflammatory cells was observed in all tissue specimens. Samples included pancreatic acini in five cases (35.7%), in number of 2 to 13 acini each. In the remaining 9 cases (64.3%) the presence of ductal epithelium together with fibrotic tissue was observed. Biopsies including pancreatic acini were those obtained from patients with mild to moderate EUS changes of chronic pancreatitis (up to 5 EUS criteria). On the contrary, biopsy samples from more severe cases (8–10 EUS criteria) were those showing only ductal ephitelium with fibrotic component. Conclusion: EUS-guided pancreatic biopsy allows evaluating histological changes of all stages of chronic pancreatitis. This may be an important advance for a better knowledge of the disease.
A2.19 HDAC3 is required for the inflammatory gene expression program in fibroblast-like synoviocytes
Authors: C Angiolilli, P Kabala, AM Grabiec, B Malvar-Fernández, DL Baeten, KA Reedquist
Journal: Annals of the Rheumatic Diseases (2015)

Three patients with progressive supranuclear palsy demonstrated atrophy of the midbrain, pons, cerebellum, and cerebral hemispheres by computed tomography with horizontal, sagittal, and coronal reconstruction. Benztropine therapy resulted in improvement of speech and gait without significantly affecting the vertical gaze palsy.
Focal Hepatitis, Fever and Skin Rash Following Therapy with Sulfamethoxypyridazine, a Long-Acting Sulfonamide
Authors: William A. Tisdale
Journal: New England Journal of Medicine (1958)

SINCE their introduction as clinical chemotherapeutic agents, the sulfonamide derivatives have been implicated repeatedly as sensitizing agents capable of producing "allergic" types of drug reactions. Although the occurrence of such untoward reactions has been greatly reduced with the newer compounds, fever, skin rashes, hematopoietic disorders and renal and hepatic dysfunction continue to complicate sulfonamide therapy in a small fraction of cases. For this reason, awareness of potential sensitization by these agents and prompt recognition of its clinical manifestations are of continuing importance.To date, only transient skin rash and drug fever1 have been listed as hypersensitivity complications of treatment with . . .
THU0387 Relationship between patterns of clinical presentation uveitis and final immunologic diagnosis:
Authors: E. Toledano, Z. Rosales, Ó. Fontseré, C. Vadillo, R. Méndez, M.Ά. Descalzo, E. Loza, E. Pato
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In our multidisciplinary uveitis unit, coordinated by ophthalmologists and rheumatologists, a predefined set of 12 clinical patterns of uveitis presentation is used to help diagnose since 1992. The routinely use of these clinical patterns leads to a decrease in the number of diagnostic test to confirm the final diagnosis. <h3>Objectives</h3> To analyse the association between these clinical patterns and the final immunologic diagnosis and its discriminative value. <h3>Methods</h3> A prospective cohort study was performed. The study was approved by the ethic committee of our hospital. All patients attended in our multidisciplinary uveitis unit from January 1992 to December 2009 who were diagnosed with uveitis were selected. In all of them the following data were collected: the clinical patterns of uveitis presentation, the initial diagnosis, the medical history, the diagnostic test results and the final diagnosis. The 12 clinical patterns of uveitis presentation are: a) anterior uveitis (AU) including 1) acute recurrent unilateral AU (ARUAU), 2) acute nonrecurrent unilateral AU (ANRUAU), 3) acute bilateral AU (ABAU), 4) chronic AU (CAU), 5) intermediate uveitis (IU); b) posterior uveitis as 6) unilateral chorioretinitis (UC), 7) bilateral chorioretinitis (BC), 8) retinal vasculitis (RV), 9) chorioretinitis panuveitis (CP), 10) vitritis panuveitis (VP), 11) retinal vasculitis panuveitis (RVP) and 12) exudative retinal detachment panuveitis (ERD). To measure the association between uveitis and immunologic diagnosis a correspondence analysis was performed with every pattern. According to the model coordinates, 3 different levels of association were established -mild, high and very high-, based on the distance and magnitude of the coordinates. The highest absolute number and the smallest distance, the strongest association. <b>Results:</b> Our data show the central diagnostic value of the clinical patterns of uveitis presentation. The use of these patterns in daily practice could definitively be a useful tool in order to diagnose, reducing therefore he number diagnostic tests, but could also help prescribe the most appropriate treatment. <h3>Conclusions</h3> Our data show the central diagnostic value of the clinical patterns of uveitis presentation. The use of these patterns in daily practice could definitively be a useful tool in order to diagnose, reducing therefore he number diagnostic tests, but could also help prescribe the most appropriate treatment. <h3>References</h3> Uveitis. Diagnosis <h3>Disclosure of Interest</h3> None Declared
THU0170 Predicted Versus Observed Radiographic Progression in a RA Randomized Trial
Authors: A. Levitsky, K. Forslind, R. F. van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Radiological progression is a key outcome in early RA. We previously developed a radiological progression prediction method based on the patient’s report of symptom duration and the radiological damage at first examination<sup>1</sup>. We previously presented data on predicted radiological progression for a subset of patients in the SWEFOT trial. Here, we applied the analysis of predicting radiological progression (prediction of progression in early RA, POPERA) to the full data set from this randomized trial. <h3>Objectives</h3> To analyze predicted versus observed radiological progression in early RA patients treated with MTX or combination therapies. <h3>Methods</h3> In the SWEFOT trial<sup>2</sup>, 487 patients with early RA were given MTX, and non-responders after 3-4 months (DAS28&gt;3.2) were randomized to MTX+SSZ+HCQ (“Triple therapy”) vs. MTX+infliximab (“anti-TNF”). The others continued on MTX (“MTX-responders”). Hand and foot X-rays (baseline, 1, and 2 years) were analyzed with the Sharp-van der Heijde scoring (SHS) method. Predicted progression at 1 and 2 years was calculated as the baseline SHS divided by symptom duration in months multiplied by 12 or 24 respectively. The analyses were based on intention-to-treat (ITT) without imputations of scores. In order to allow inclusion of patients with SHS 0 at baseline in the mathematical model all SHS values in the entire data set were increased by 1. Additional analyses focused on randomized patients who discontinued the trial (i.e. treatment “failure”) and on patients who maintained treatment for 2 years (“completers”). Comparisons between observed progressions were done by non-parametric, Mann-Whitney U testing. <h3>Results</h3> The prediction model was applied to 362 patients out of 405 who were eligible. Reasons for exclusion were primarily missing baseline data. In patients who had failed both MTX monotherapy and subsequent triple therapy, the radiological reduction was numerically the least at 12 months (40.7%). In all three groups of patients, observed radiological progression was reduced from predicted by 50-94% (Table I). After 12 months, there were no significant between-group differences. After 24 months, progression was reduced more in the anti-TNF arm than in both the MTX and triple therapy arms. <h3>Conclusions</h3> The progression observed in patients who failed their first 2 antirheumatic therapies was 59.3% of predicted, indirectly supporting the validity of this method. The overall results demonstrated significant reductions from predicted radiological progression in patient groups who were successfully treated with MTX and in those who were included in either group of the randomization. Over 24 months, anti-TNF therapy was superior to triple therapy. <h3>References</h3> Wick et al. Ann Rheum Dis 64:134-137, 2005 Van Vollenhoven et al. Lancet 374:459-466, 2009. <h3>Disclosure of Interest</h3> None Declared
Abstract 4953: Stromal endosialin modulates the proinflammatory tumor microenvironment and is crucial for the growth of orthotopic pancreatic tumors.
Authors: Sven Christian, Vijaysahankar Sivanandam, Michael Strerath, Heiner Apeler, Holger Hess-Stumpp, Hellmut G. Augustin
Journal: Cancer Research (2013)

Abstract Endosialin (CD248), a transmembrane protein expressed in stromal fibroblasts and activated pericytes during embryonic development, is expressed in human carcinomas. Although its function is unknown, due to its highly specific expression pattern endosialin represents a promising anti-tumor target. To unravel the role of endosialin during tumor progression and metastasis, we employed systematic loss-of-function approaches in stromal fibroblasts in vitro as well as in subcutaneous and orthotopic tumors in vivo. These experiments revealed an important role of endosialin in regulating fibroblast proliferation and in orchestrating an inflammatory response by modulating the secretion of inflammatory cytokines (IL6) in stromal fibroblasts. The proinflammatory environment created by activated fibroblasts is thought to support tumor growth and metastasis in vivo. Experiments in endosialin-deficient mice confirmed an important role of endosialin in tumor progression in highly stroma-recruiting orthotopic pancreatic tumor models. Finally, lung metastases were dramatically decreased in endosialin-deficient mice supporting a role of a proinflammatory tumor stroma in tumor dissemination. Taken together, our experiments identify endosialin as an important modulator of stromal responses that are crucial for tumor progression and metastasis. Endosialin may therefore represent a novel target for development of anticancer therapies for solid tumors. Citation Format: Sven Christian, Vijaysahankar Sivanandam, Michael Strerath, Heiner Apeler, Holger Hess-Stumpp, Hellmut G. Augustin. Stromal endosialin modulates the proinflammatory tumor microenvironment and is crucial for the growth of orthotopic pancreatic tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4953. doi:10.1158/1538-7445.AM2013-4953
Abstract LB-297: The EMT inhibitor AB-16B5 interacts with specific isoforms of secreted clusterin
Authors: Gilles B. Tremblay, Elisabeth Viau, Mario Filion
Journal: Cancer Research (2012)

Abstract Secreted clusterin (sCLU) exhibits elevated expression in several cancer indications. sCLU plays a pro-survival role in tumors and, more recently, it was found to be a potent stimulator of the epithelial-to-mesenchymal transition (EMT). These findings led to the development of a monoclonal antibody, AB-16B5, that interacts with a specific EMT-inducing domain in sCLU resulting in abrogation of migration and invasion of many types of cancer cells. We previously showed that blocking tumor-associated sCLU with AB-16B5 reduced the expression of mesenchymal markers and restored the expression of epithelial markers in human tumor xenografts, observations that were in line with inhibition of EMT in vivo. Consequently, this resulted in reduced metastatic invasion and increased response to cytotoxic agents in animal models of human cancer. We now report new results that shed light on the biochemical differences between sCLU that is secreted by tumor cells or normal cells. Using two-dimensional gel electrophoresis, we found that there was a difference in the number and composition of sCLU isoforms present in the plasma of cancer patients compared with those expressed in healthy individuals. In particular, the post-translational modifications were more complex on sCLU secreted from tumor cells compared with those present in sCLU from healthy individuals. Moreover, AB-16B5 was found to specifically interact with several of the isoforms expressed from tumor cells but exhibited a reduced ability to interact with sCLU from plasma from healthy individuals. We also examined the interaction between AB-16B5 and tumor-associated sCLU in vivo. In these studies, injection of AB-16B5 conjugated to a fluorophore in mice harboring sub-cutaneously implanted human pancreatic tumor xenografts resulted in a rapid enrichment of fluorescence signal in the tumors. Interestingly, administration of high concentrations of human recombinant sCLU immediately prior to injection of the AB-16B5 fluorophore-conjugate still resulted in enrichment of fluorescence signal in the tumors, albeit at slightly lower intensity than was observed in the absence of recombinant sCLU. Our findings indicate that AB-16B5 can efficiently interact with tumor-associated sCLU despite the presence of excess concentrations of sCLU in the circulation. Taken together, our results suggest that AB-16B5 has increased affinity for sCLU isoforms that are specifically expressed from tumor cells that have undergone an EMT. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-297. doi:1538-7445.AM2012-LB-297
Reply to Peng &amp; Chow
Authors: Y. Lee, J. Moon, H. Choi
Journal: Endoscopy (2013)

We appreciate the comments of Peng & Chow on our study “Direct peroral cholangioscopy using an ultraslim upper endoscope for management of residual stones after mechanical lithotripsy for retained common bile duct stones” [1]. There are many factors that contribute to the presence of residual bile duct stones after stone extraction [2]. Although the maximum size of residual stones in our study was 9 mm, we have performed various procedures to confirm and remove residual bile duct stones. Despite such efforts, residual stones still occur because risk factors for residual stones are various, so more improved methods for diagnosis and treatment are necessary.